Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY

NCT03519178 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03519178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03519178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Terminated
Start date
March 7, 2018
Completion date
October 30, 2024
Enrollment
155 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

hr+ her2- metastatic breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, triple negative breast cancer, male breast cancer